Serum can inhibit reversal of multidrug resistance by chemosensitisers
M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), S. E. Salmon(University of Arizona), Rita de Giuli(Kantonsspital St. Gallen), William S. Dalton(Texas Oncology), Kathleen Kunke(University of Arizona), Scott S. Emerson(Cleveland Clinic Lerner College of Medicine)
Cited by 25
Related Papers
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799